Veradermics (MANE) Chief R&D Officer David Hollander Receives Award

What happened

• David Hollander, Chief Research & Development Officer of Veradermics, received equity awards on 2026-09-01: 9,650 shares as restricted stock units (RSUs) and 19,300 derivative awards (reported as a derivative grant). Both grants were reported at $0.00 per share, so no cash changed hands on grant.

Key details

• Transaction date: September 1, 2026. Form 4 filed September 3, 2026 (timely filing).
• Award amounts and reported price: 9,650 RSUs @ $0.00; 19,300 derivative award units @ $0.00. Combined total = 28,950 award units; reported value at grant = $0.
• Vesting (per filing footnotes):
  • RSUs (9,650): vest 25% on each anniversary of the grant date — Sept 1 of 2027, 2028, 2029, and 2030 — subject to continued service.
  • Derivative award (19,300): vests 25% on Sept 1, 2027 (first anniversary), then the remaining shares vest in equal monthly installments over the following 36 months, subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Filing timeliness: filed 2 days after the grant date (no late filing flag in the record provided).

Context

• These entries are grants/awards (not open‑market purchases or sales). RSUs are contingent rights to receive shares if vesting conditions are met; the derivative award appears to be an option-style grant with a multi‑year vesting schedule. Grants do not imply immediate stock sales or inflows and are commonly used for employee compensation and retention.